Drugs / GDC-0587
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07214662 | Jan 2026 → Jun 2030 expected | breast cancer | Genentech, Inc. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GDC-0587 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07214662 ↗ |
| Action | Inhibit | “GDC-0587 (cyclin-dependent kinase-4 \[CDK4\] inhibitor)” NCT07214662 ↗ |
| Route | Oral | “Participants will receive GDC-0587 orally as per the schedule in the protocol.” NCT07214662 ↗ |
| Target | CDK4 | “GDC-0587 (cyclin-dependent kinase-4 \[CDK4\] inhibitor)” NCT07214662 ↗ |